SNX9 Antibody

What is SNX9 and what are its key cellular functions?

SNX9 belongs to the sorting nexin family of proteins containing phospholipid-binding PX domains. It plays critical roles in multiple cellular processes:

• Membrane trafficking and protein sorting: SNX9 can bind specific phospholipids and form protein-protein complexes involved in cellular membrane trafficking .

• T cell signaling: SNX9 is recruited to the immunological synapse during T cell activation and regulates CD28 signaling. It mediates membrane tubulation that promotes CD28 triggering and downstream signaling events .

• Cancer biology: SNX9 functions as a negative regulator of invadopodia formation in cancer cells. Depletion of SNX9 increases both the number of cells expressing invadopodia and the number of invadopodia per cell in multiple cancer cell lines, including MDA-MB-231, SCC61, and HT1080 .

• T cell exhaustion: SNX9 has been identified as a mediator of T cell exhaustion. Its deletion decreases PLCγ1, Ca2+, and NFATc2-mediated T cell signaling while enhancing memory differentiation and IFNγ secretion of adoptively transferred T cells .

What applications are SNX9 antibodies validated for?

SNX9 antibodies have been validated for multiple experimental applications, with specific dilution recommendations:

It is recommended to optimize these dilutions for each specific experimental system to obtain optimal results .

What is the expected molecular weight of SNX9?

While the calculated molecular weight of SNX9 is 67 kDa (595 amino acids), the observed molecular weight in SDS-PAGE is typically around 78 kDa . This discrepancy is likely due to post-translational modifications or the protein's structural properties affecting migration in gels. When validating a new SNX9 antibody, researchers should expect to observe a band at approximately 78 kDa.

Where is SNX9 typically localized in cells?

SNX9 shows dynamic localization depending on cellular context:

• In T cells, SNX9 is recruited to the immunological synapse upon activation. Live imaging and 3D reconstructions show that SNX9 is enriched close to the contact surface at the immunological synapse, identified by TCRζ-EGFP signal .

• SNX9 clusters at active immune synapses in primary human CD8 T cells with co-localization with the central supramolecular activation cluster (cSMAC) components TCRz (CD3ζ) and CD28. Only marginal co-localization is observed with the distal SMAC (dSMAC) component CD45, or with LFA1 and lytic granules .

• In cancer cells, SNX9 can be found at invadopodia structures, where it plays a regulatory role .

How should I optimize immunofluorescence staining protocols for SNX9?

For optimal immunofluorescence staining of SNX9:

• Fixation: Use 4% paraformaldehyde for 10-15 minutes at room temperature. Overfixation may mask epitopes.

• Permeabilization: Use 0.1-0.2% Triton X-100 for 5-10 minutes. For membrane-associated SNX9, consider gentler permeabilization using 0.1% saponin.

• Blocking: Block with 3-5% BSA or 5-10% normal serum from the species of the secondary antibody for 1 hour.

• Primary antibody: Dilute SNX9 antibody between 1:50 to 1:500 as recommended, but optimize for your specific application .

• Co-staining recommendations:

  • For immune synapse studies: Co-stain with TCRζ and CD28 to visualize cSMAC

  • For cancer cell studies: Co-stain with actin and cortactin to visualize invadopodia

• Controls: Include a negative control (isotype control or secondary antibody only) and a positive control (cell line known to express SNX9, such as HeLa cells) .

What are the best sample preparation methods for Western blotting of SNX9?

For optimal Western blot results with SNX9 antibodies:

• Lysis buffer: Use RIPA buffer supplemented with protease inhibitors. For phosphorylation studies, include phosphatase inhibitors.

• Protein loading: Load 20-40 μg of total protein per lane.

• Gel percentage: Use 8-10% SDS-PAGE gels for optimal resolution around the 78 kDa mark.

• Transfer conditions: Transfer to PVDF membrane at 100V for 60-90 minutes or overnight at 30V at 4°C.

• Blocking: Block with 5% non-fat milk in TBST for 1 hour at room temperature.

• Antibody dilution: Dilute primary SNX9 antibody between 1:1000 to 1:8000 in blocking buffer .

• Positive controls: Include lysates from HeLa cells or heart tissue samples as positive controls .

• Expected band: Look for a band at approximately 78 kDa .

How do I optimize SNX9 antibody use for studying immune synapses?

When using SNX9 antibodies to study immune synapses:

• Cell system selection:

  • Jurkat T cells with Raji B cells (±SEE) provide a controlled system for immune synapse formation

  • Primary T cells with dendritic cells offer a more physiologically relevant model

• Timing considerations: SNX9 recruitment to the immunological synapse occurs early (from 2 minutes onwards) and increases over time, with approximately 75% of conjugates showing SNX9 at the synapse after 15 minutes of activation .

• Co-visualization strategies:

  • Use phalloidin-Alexa488 to detect F-actin to identify the synapse

  • Co-express fluorescently tagged TCRζ for synapse identification

  • Co-stain for CD28 to examine co-localization with SNX9 at the cSMAC

• Advanced imaging approaches:

  • For dynamic studies, express SNX9-mCherry and TCRζ-EGFP in Jurkat cells

  • Use 3D reconstructions to visualize SNX9 enrichment at the synapse

  • Consider total internal reflection fluorescence (TIRF) microscopy for enhanced resolution at the cell-substrate interface

How can I use SNX9 antibodies to study T cell exhaustion?

To study the role of SNX9 in T cell exhaustion:

• Model system development: Utilize the human ex vivo exhaustion model described by Schmitt et al. to generate tumor antigen-specific exhausted T cells that resemble patient-derived T cells on phenotypic and transcriptional levels .

• Markers to assess alongside SNX9:

  • Exhaustion markers: PD-1 (PDCD1), TIM-3 (HAVCR2)

  • Exhaustion-related transcriptional regulators: TOX, TOX2

  • Memory/progenitor markers: CCR7, TCF7

  • SNX9 expression correlates negatively with CCR7 and TCF7 expression and positively with exhaustion markers

• Functional assays following SNX9 modulation:

  • Measure PLCγ1, Ca2+, and NFATc2-mediated T cell signaling

  • Assess IFNγ secretion

  • Evaluate memory differentiation markers

  • Test anti-tumor efficacy in adoptive transfer models

• Validation in patient samples: Consider quantifying the percentage of SNX9+ cells among CD8 T cells as a potential biomarker for immunotherapy response, as high SNX9 expression has been associated with poor response to immune checkpoint blockade in melanoma patients .

What controls and validation methods should I use when studying SNX9 knockout/knockdown?

For rigorous validation of SNX9 modulation experiments:

• Knockout/knockdown validation methods:

  • Western blot analysis using validated anti-SNX9 antibodies

  • qPCR to confirm reduction at mRNA level

  • Immunofluorescence to confirm protein loss in individual cells

• Functional validation approaches:

  • For T cells: Assess changes in CD28 phosphorylation, NFAT nuclear translocation, and IL-2 production upon T cell activation

  • For cancer cells: Quantify invadopodia formation (number of cells with invadopodia and number of invadopodia per cell)

• Essential controls:

  • Non-targeting siRNA/sgRNA controls

  • Rescue experiments with exogenous SNX9 expression to confirm phenotype specificity

  • Isogenic wild-type controls

• Addressing compensatory mechanisms:

  • Consider potential upregulation of other sorting nexin family members

  • Perform acute (inducible) knockout/knockdown to minimize compensation

How do I interpret SNX9 colocalization with membrane structures?

When analyzing SNX9 colocalization with membrane structures:

• Expected patterns:

  • In T cells, SNX9 shows clustering at active immune synapses with qualitative co-localization with cSMAC components TCRz (CD3ζ) and CD28, but only marginal co-localization with dSMAC component CD45 or with LFA1 and lytic granules .

  • SNX9 forms tubules at the immunological synapse that are connected to CD28 clusters at the plasma membrane .

• Quantification approaches:

  • Use Pearson's correlation coefficient or Manders' overlap coefficient for colocalization analysis

  • Consider distance-based measurements to quantify proximity to specific structures

  • Implement line scan analysis across membrane structures to visualize intensity profiles

• Dynamic analysis considerations:

  • SNX9 recruitment to the immunological synapse is time-dependent, starting at 2 minutes after activation and increasing over time

  • Live-cell imaging with tagged constructs allows tracking of dynamic changes in localization

• Advanced imaging techniques:

  • Super-resolution microscopy (STORM, PALM, SIM) for nanoscale resolution of membrane structures

  • FRET analysis for direct protein-protein interactions in membrane microdomains

What are the methodological considerations for using SNX9 antibodies in cancer research?

When studying SNX9 in cancer contexts:

• Experimental models:

  • Multiple cancer cell lines show SNX9-regulated invadopodia formation, including MDA-MB-231 (breast cancer), SCC61 (oral squamous carcinoma), and HT1080 (fibrosarcoma)

  • Consider using patient-derived samples for clinical relevance

• Key assays and their optimization:

  • Invadopodia formation: Plate cells on gelatin-coated coverslips and co-stain for actin and cortactin

  • Invadopodia functionality: Use collagen-coated filters with 1-μm-diameter pores to assess protrusion formation

  • Matrix degradation: Fluorescently labeled gelatin degradation assays

• SNX9 interaction partners to investigate:

  • TKS5: A direct or indirect binding partner of SNX9 in invadopodia

  • RhoA and Cdc42: SNX9 regulates these GTPases that are master regulators of the actin cytoskeleton at invadopodia

• Controls and quantification methods:

  • Quantify both the percentage of cells with invadopodia and the number of invadopodia per cell

  • Assess invadopodia maturity through matrix degradation assays

  • Use appropriate statistical tests for comparing control and experimental conditions

How do I troubleshoot weak or nonspecific signals with SNX9 antibodies?

When encountering issues with SNX9 antibody performance:

• Weak signal in Western blot:

  • Increase protein loading (up to 50-60 μg)

  • Decrease antibody dilution (use more concentrated antibody)

  • Extend incubation time (overnight at 4°C)

  • Use enhanced chemiluminescence (ECL) substrate with higher sensitivity

  • Ensure transfer efficiency (consider total protein stain on membrane)

• High background in immunostaining:

  • Increase blocking time and/or concentration

  • Use more stringent washing (longer or additional washes)

  • Titrate antibody to find optimal concentration

  • Consider using different blocking reagents (BSA vs. serum)

  • Filter antibody solutions before use

• Non-specific bands in Western blot:

  • Increase blocking time/concentration

  • Use more stringent washing

  • Titrate antibody to find optimal concentration

  • Consider using different blocking reagent

  • Validate with positive and negative controls (knockout/knockdown samples)

• Inconsistent results between experiments:

  • Standardize sample preparation protocols

  • Use fresh antibody aliquots

  • Maintain consistent incubation times and temperatures

  • Include internal controls in each experiment

What are the best practices for storing and handling SNX9 antibodies?

For optimal antibody performance and longevity:

• Storage conditions:

  • Store antibodies at -20°C for long-term storage

  • Antibodies in PBS with 0.02% sodium azide and 50% glycerol pH 7.3 are stable for one year after shipment

  • Aliquoting is generally unnecessary for -20°C storage of antibodies in glycerol buffer

• Handling recommendations:

  • Avoid repeated freeze-thaw cycles

  • Allow antibody to equilibrate to room temperature before opening

  • Briefly centrifuge vials before opening to collect liquid at the bottom

  • Use sterile technique when handling antibody solutions

• Working solution preparation:

  • Dilute antibodies in fresh buffer immediately before use

  • For Western blot, dilute in 5% BSA or non-fat milk in TBST

  • For immunofluorescence, dilute in blocking buffer

• Quality control measures:

  • Test new antibody lots against previous lots

  • Include positive controls in each experiment

  • Document lot numbers and performance for reproducibility

How can SNX9 antibodies be used in studying CAR-T cell therapy optimization?

Recent research has identified SNX9 as a potential target for enhancing CAR-T cell therapies:

• Relevance to CAR-T cell therapy:

  • SNX9 knockout enhances memory differentiation and IFNγ secretion of adoptively transferred T cells

  • SNX9 deletion results in improved anti-tumor efficacy of human chimeric antigen receptor T cells in vivo

• Experimental approaches:

  • Use SNX9 antibodies to monitor SNX9 expression levels in CAR-T cells

  • Correlate SNX9 expression with CAR-T cell persistence and efficacy

  • Monitor SNX9 expression during different manufacturing protocols

• Functional assays:

  • Measure long-term persistence using SNX9 as a biomarker

  • Compare effector functions between SNX9-high and SNX9-low CAR-T populations

  • Assess memory formation in relation to SNX9 expression levels

• Translational applications:

  • Consider SNX9 knockout/knockdown as a strategy to enhance CAR-T cell persistence and efficacy

  • Develop screening protocols to identify CAR-T preparations with optimal SNX9 expression profiles

What are the considerations for multiplexing SNX9 antibodies with other markers?

For comprehensive analysis of SNX9 in complex biological contexts:

• Compatible marker combinations:

  • T cell exhaustion panel: SNX9 + PD-1 + TIM-3 + TOX + TCF7

  • Immune synapse panel: SNX9 + CD3ζ + CD28 + CD45 + F-actin

  • Cancer/invadopodia panel: SNX9 + actin + cortactin + TKS5

• Technical considerations:

  • Select primary antibodies from different host species to avoid cross-reactivity

  • Use directly conjugated antibodies when possible to reduce background

  • Consider spectral overlap when selecting fluorophores

  • Perform proper compensation controls for flow cytometry

  • Sequential staining may be necessary for co-localization with multiple markers from the same host species

• Advanced multiplexing techniques:

  • Cyclic immunofluorescence for high-parameter imaging

  • Mass cytometry (CyTOF) for high-dimensional analysis

  • Spectral flow cytometry for increased parameter number

• Analysis approaches:

  • Use dimensionality reduction techniques (tSNE, UMAP) for high-parameter data

  • Consider spatial analysis tools for tissue imaging data

  • Implement machine learning for pattern recognition in complex datasets